argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 feb 2016 - 07:00
Statutaire naam
argenx SE
Titel
argenx opens clinical trial sites in South Korea for ARGX-111 program
Bericht
Breda, the Netherlands/Ghent, Belgium, 18 Febr 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, today announced the opening of three clinical trial sites in South Korea for the recruitment of MET-amplified cancer patients for the Phase 1 safety expansion cohort of ARGX-111.
"The prevalence of cancer patients with MET-amplification is higher in Asia so we are very excited to have opened these clinics to facilitate the recruitment process into the ARGX-111 program", commented Tim Van Hauwermeiren, CEO at argenx. "Expanding our clinical trials into Asia is the first step towards increasing our presence in this region and becoming a globally active company. We hope this strategy will allow us more diverse enrollment capabilities and the possibility of new collaborations."
Gerelateerde downloads
Datum laatste update: 20 december 2025